Fig. 3From: Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson’s disease: the LEAP-studyFlow chart LEAP-study. Taking into account a withdrawal rate of 25 %, 446 patients need be enrolled to be able to show a minimal clinically relevant difference of four points on the total UPDRS at the end of the studyBack to article page